Table 1 Patient covariates (N = 43).
From: Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Male | 29 |
Age (Median; range) | 24 (4–60) |
Donor | |
HLA-identical sibling | 17 |
HLA-haplotype-matched | 26 |
Graft | |
Blood | 17 |
Blood and bone marrow | 26 |
BCR/ABL1 positive | |
Yes | 5 |
No | 38 |
Cytogenetics | |
Abnormal | 14 |
Normal | 29 |
Mutation | |
Yes | 23 |
No | 20 |
Transplant conditioning regimen | |
BU/CY | 17 |
BU/CY/Ara-C/CCNU | 26 |
Posttransplant immune suppression | |
CSA/MMF/MTX | 17 |
Tacrolimus/MMF/ATG/MTX | 26 |
Interval from transplant to relapse (mo; median; range) | 8 (1–25) |
Interval from relapse to CAR-T (d; median; range) | 42 (35–59) |
Therapy for relapse | |
Stop immune suppression | 12 |
DLI | 7 |
Chemotherapy | 19 |
Chemotherapy/DLI | 5 |
Bone marrow blasts pre infusion | |
0.01-(MRD-positive) | 13 |
5–50% | 20 |
>50% | 10 |
Co-stimulatory molecular | |
CD28 | 18 |
4–1BB | 25 |
Preinfusion therapy | |
Regimen 1 | 34 |
Regimen 2 | 5 |
Regimen 3 | 4 |
CAR-T cell dose (×10E + 6/kg; median; range) | 1.76 (0.4–12) |
<1 | 4 |
1~2 | 26 |
>2 | 13 |
